157 related articles for article (PubMed ID: 31297986)
1. Incidence and patterns of malignancies in a multi-ethnic cohort of rheumatoid arthritis patients.
Lim XR; Xiang W; Tan JWL; Koh LW; Lian TY; Leong KP; Koh ET;
Int J Rheum Dis; 2019 Sep; 22(9):1679-1685. PubMed ID: 31297986
[TBL] [Abstract][Full Text] [Related]
2. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
3. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis.
Simon TA; Thompson A; Gandhi KK; Hochberg MC; Suissa S
Arthritis Res Ther; 2015 Aug; 17(1):212. PubMed ID: 26271620
[TBL] [Abstract][Full Text] [Related]
4. The Risk of Malignancy in Korean Patients with Rheumatoid Arthritis.
Lee H
Yonsei Med J; 2019 Feb; 60(2):223-229. PubMed ID: 30666845
[TBL] [Abstract][Full Text] [Related]
5. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate.
Buchbinder R; Barber M; Heuzenroeder L; Wluka AE; Giles G; Hall S; Harkness A; Lewis D; Littlejohn G; Miller MH; Ryan PF; Jolley D
Arthritis Rheum; 2008 Jun; 59(6):794-9. PubMed ID: 18512713
[TBL] [Abstract][Full Text] [Related]
6. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.
Harigai M; Nanki T; Koike R; Tanaka M; Watanabe-Imai K; Komano Y; Sakai R; Yamazaki H; Koike T; Miyasaka N
Mod Rheumatol; 2016 Sep; 26(5):642-50. PubMed ID: 26873430
[TBL] [Abstract][Full Text] [Related]
7. The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study.
Lin YC; Chou HW; Tsai WC; Yen JH; Chang SJ; Lin YC
Clin Rheumatol; 2015 Jul; 34(7):1195-202. PubMed ID: 25990004
[TBL] [Abstract][Full Text] [Related]
8. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study.
Berghen N; Teuwen LA; Westhovens R; Verschueren P
Clin Rheumatol; 2015 Oct; 34(10):1687-95. PubMed ID: 26219489
[TBL] [Abstract][Full Text] [Related]
9. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.
Mercer LK; Davies R; Galloway JB; Low A; Lunt M; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2013 Jan; 52(1):91-8. PubMed ID: 23238979
[TBL] [Abstract][Full Text] [Related]
10. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
Cho SK; Lee J; Han M; Bae SC; Sung YK
Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
[TBL] [Abstract][Full Text] [Related]
11. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment.
Simon TA; Smitten AL; Franklin J; Askling J; Lacaille D; Wolfe F; Hochberg MC; Qi K; Suissa S
Ann Rheum Dis; 2009 Dec; 68(12):1819-26. PubMed ID: 19054822
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, incidence, and risk factors of malignancy in patients with rheumatoid arthritis: a nationwide cohort study from Korea.
Ko KM; Moon SJ
Korean J Intern Med; 2023 Jan; 38(1):113-124. PubMed ID: 34407599
[TBL] [Abstract][Full Text] [Related]
13. Rheumatoid arthritis and the risk of malignancy.
Cibere J; Sibley J; Haga M
Arthritis Rheum; 1997 Sep; 40(9):1580-6. PubMed ID: 9324011
[TBL] [Abstract][Full Text] [Related]
14. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
[TBL] [Abstract][Full Text] [Related]
15. Trends in risks of malignancies in Japanese patients with rheumatoid arthritis: Analyses from a 14-year observation of the IORRA cohort.
Sugimoto N; Tanaka E; Inoue E; Abe M; Sugano E; Sugitani N; Saka K; Ochiai M; Higuchi Y; Yamaguchi R; Ikari K; Nakajima A; Yamanaka H; Harigai M
Mod Rheumatol; 2023 Jul; 33(4):715-722. PubMed ID: 35920098
[TBL] [Abstract][Full Text] [Related]
16. Risk of malignancy among patients with rheumatic conditions.
Thomas E; Brewster DH; Black RJ; Macfarlane GJ
Int J Cancer; 2000 Nov; 88(3):497-502. PubMed ID: 11054684
[TBL] [Abstract][Full Text] [Related]
17. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
Wolfe F; Michaud K
Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis.
Smitten AL; Simon TA; Hochberg MC; Suissa S
Arthritis Res Ther; 2008; 10(2):R45. PubMed ID: 18433475
[TBL] [Abstract][Full Text] [Related]
19. Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study.
Cordtz R; Mellemkjær L; Glintborg B; Hetland ML; Madsen OR; Jensen Hansen IM; Dreyer L
Rheumatology (Oxford); 2016 Jun; 55(6):1017-22. PubMed ID: 26912584
[TBL] [Abstract][Full Text] [Related]
20. Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: Will immunosuppressants work?
Zhang Y; Lin J; You Z; Tu H; He P; Li J; Gao R; Liu Z; Xi Z; Li Z; Lu Y; Hu Q; Li C; Ge F; Huo Z; Qiao G
Front Immunol; 2022; 13():1050876. PubMed ID: 36605209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
